Navigation Links
Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology

l chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule anti-ischemics and antithrombotics towards human clinical studies.


This press release contains forward-looking statements, as defined under applicable securities legislation, that involve risks, which may cause actual results to differ materially from the statements made, and accordingly may be deemed to be forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise except as required by law. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the Company's stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence on collaborative partners and the ability to meet its debt obligations. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Additional risks and uncertainties relating to the Company and its business can be found in the "Risk Factors" section of its Form 20F for the year ended May 31, 2006.

For more information, please contact:

Derek Reimer Adam Peeler

Chief Financial Officer Manager of Investor & Public Relations


Tel.
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Protox Announces Positive Clinical Data from Prostate Cancer Study
4. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
6. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
7. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
11. Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29
Post Your Comments:
(Date:8/29/2014)... 29, 2014 According to ... & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), ... QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global ... Oligonucleotide Synthesis Market is expected to reach $1,712.1 ... growing at a CAGR of 9.8% from 2014 ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... VANCOUVER, British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" ... 2014 fiscal year-end financial statements.  The Company recently changed ... to facilitate an application to list its common stock ... possible. DelMar,s financial statements as filed with ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
(Date:9/1/2014)... More than 200 Lipitor lawsuit ( http://www.thelipitorlawsuit.com/ ... that continues to progress in the U.S. District Court, ... , A federal Case List published on August 15th ... medication by plaintiffs who developed Type 2 diabetes allegedly ... failed to adequately warn patients and their doctors about ...
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. 29, 2014 (HealthDay ... American aid workers successfully cured a group of monkeys infected ... The drug, ZMapp, prompted recovery in all 18 monkeys who ... five days after infection. ZMapp even cured monkeys with ... away from death, said study senior author Gary Kobinger, chief ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 As well ... training, Derek is currently pursuing counselor certification in Louisiana. ... advance through the CPI training program as well as ... I have grown both personally and professionally. I ... I am competently able to do so. As ...
(Date:9/1/2014)... York (PRWEB) September 01, 2014 ... retrieve, organize and analyze biological and genetic data. ... the activity of developing software tools to generate ... to be confused with biological computation. While bioinformatics ... understanding of biology can its related concepts, biological ...
(Date:9/1/2014)... Secaucus, NJ (PRWEB) September 01, 2014 Registration ... For The Warriors® 5K and 1-Mile Race to be held ... at The Plaza Court Yard at Harmon Meadow in Secaucus, ... For The Warriors®, a national nonprofit dedicated to restoring a ... for our service members and our military families. , General ...
Breaking Medicine News(10 mins):Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2
... For the first time, universal standards to guide ... labels to reflect how patients read and understand medication ... labels can vary significantly from pharmacy to pharmacy, even ... the safe use of medications. The new standards, developed ...
... hills . . . They might get a pedestrian ... someone in an electric wheelchair, they could mean terrain ... To address this problem, researchers at the Florida A&M ... technology that will enable electric-powered wheelchairs to detect hazardous ...
... into a collaborative agreement with Veridex LLC to establish ... cell (CTC) technologies. The overall goal of the agreement ... and characterizing CTCs, solid tumor cells found at extremely ... key to noninvasive characterization of cancer and potentially to ...
... and other developing countries is seasonal, linked to farm ... according to an international team of researchers from Uganda ... approach to this problem is prevention. "Hydrocephalus in infants ... Steven Schiff, the Brush Chair professor of engineering and ...
... a clear association of tuberculosis with lung cancer remains ... January issue of the Journal of Thoracic Oncology ... among people with tuberculosis. Researchers at China Medical ... patients covered under the country,s National Health Insurance (NHI) ...
... Dec. 31 (HealthDay News) -- Two to three times more ... and New Year,s than over comparable periods of time during ... on Alcohol Abuse and Alcoholism. The agency also noted ... an impaired driver, compared to 28 percent for the rest ...
Cached Medicine News:Health News:Universal standards proposed for prescription container labels to help reduce medication misuse 2Health News:Universal standards proposed for prescription container labels to help reduce medication misuse 3Health News:FSU researchers helping electric-wheelchair users move more easily 2Health News:FSU researchers helping electric-wheelchair users move more easily 3Health News:Mass. General enters collaboration to develop new approach to capturing circulating tumor cells 2Health News:Infant hydrocephalus, seasonal and linked to farm animals in Uganda 2Health News:Infant hydrocephalus, seasonal and linked to farm animals in Uganda 3Health News:Infant hydrocephalus, seasonal and linked to farm animals in Uganda 4Health News:Study finds evidence of increased lung cancer risk among tuberculosis patients 2Health News:Holiday Drinking Raises Death Toll on U.S. Roads, Experts Warn 2
... stereopsis from 800 to 40 ... young as 2 years of ... from left to right., ,Randot ... Book #1: 200 & 100 ...
... The Standard for Stereo Depth Perception. ... 1200 sec or arc) and Fine ... Circle Test (800 to 40 sec ... (400 to 100 sec of arc), ...
The Emit Phenytoin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of phenytoin in human serum or plasma....
The Emit 2000 Phenytoin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of phenytoin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartrid...
Medicine Products: